The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I first-in-human trial of ABT-301, an oral pan-HDAC inhibitor, in patients with advanced solid tumors.
 
Chia-Chi Lin
Honoraria - Daiichi Sankyo; Lilly; Novartis; Novartis; Roche
Consulting or Advisory Role - Abbvie; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; IMPAC Medical Systems; Novartis; PharmaEngine
Travel, Accommodations, Expenses - BeiGene; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; IMPAC Medical Systems; Lilly
 
Tom Wei-Wu Chen
No Relationships to Disclose
 
Her-Shyong Shiah
No Relationships to Disclose
 
Kien Thiam Tan
Employment - Anbogen Therapeutics
 
Chien-Ting Lin
Employment - Anbogen Therapeutics
 
Tzu-An Hsu
No Relationships to Disclose
 
Meng-Chieh Lin
Employment - Anbogen Therapeutics
 
Jing-Ping Liou
No Relationships to Disclose
 
Shiow-Lin Pan
Stock and Other Ownership Interests - Calgent Biotechnology
Patents, Royalties, Other Intellectual Property - patent owned by Taipei Medical University
 
Han-Li Huang
No Relationships to Disclose
 
Ting-Yi Sung
Patents, Royalties, Other Intellectual Property - hold patent
 
Mei-Jung Lai
No Relationships to Disclose
 
Chun-Han Chen
No Relationships to Disclose